Please enable Javascript to use all features and improve your user experience.
EHC 2024
Programme
Posters
Search
EN
Back
Poster session
PoS 2
ePoster 01
Appointment
Date:
05.12.
Time:
11:00
–
12:00
Location / Stream:
ePoster station 1
Programme
ePoster
P092
Eptinezumab treatment in patients with previous anti-CGRP(R) monoclonal antibodies therapy (mAbs) – a retrospective study of real-world clinical evidence of efficacy
Alessia Bellotti (Milano, IT)
ePoster
P093
Effectiveness and tolerability of lasmiditan in the acute migraine treatment (DART) – a real-world multicentric study
Gloria Vaghi (Pavia, IT)
ePoster
P094
Evaluating safety, effectiveness, and impact on multiple sclerosis disease course of Anti-CGRP monoclonal antibodies combined with disease-modifying treatments – a multicentric study
Marina Romozzi (Rome, IT)
ePoster
P095
A multidisciplinary multicentric approach to the identification of BIOmarkers of MIGraine (BIOMIGA project): an open-label, prospective biochemical study based on the stratification of responders to Erenumab
Maria Magdalena Pocora (Pavia, IT)
ePoster
P096
Effectiveness and tolerability of fremanezumab in real-world clinical practice:Results of the 24-month prospective observational study FINESSE
Andreas Straube (Munich, DE)
ePoster
P097
Real-world long-term effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway – subgroup analysis of the FINESSE full analysis
Andreas Straube (Munich, DE)
ePoster
P098
Lessons with fremanezumab as the third CGRP antibody in our hospital: focus on factors predicting response
Marcos Polanco Fernández (Santander, ES)
ePoster
P099
Restarting migraine preventive treatment with CGRP antibodies after drug holiday: Insights from Pavia real-world experience
Luca Costantino (Pavia, IT)
ePoster
P100
Clinical impact of Rimegepant in acute migraine management for triptan non-responders
Davide Mascarella (Bologna, IT)
ePoster
P101
Switching anti-CGRP monoclonal antibodies benefits 25% of non-responders – an observational study of 82 cases
Albert Muñoz-Vendrell (Barcelona, ES)
ePoster
P102
Evaluating the efficacy of monoclonal antibodies targeting CGRP in migraine treatment and the effect of combination therapy with Onabotulinum Toxin Type-A – a retrospective study
Andreia Costa
ePoster
P103
Characteristics of people with migraine using rimegepant in the Adelphi migraine Disease Specific Programme
TM
(DSP)
Lucy Abraham (Tadworth, GB)
v1.20.0
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy